What is the appropriate meropenem dosing regimen for an adult with end‑stage renal disease who is initiating intermittent hemodialysis?

Meropenem Dosing for Adult Patients Initiating Intermittent Hemodialysis

For an adult with end-stage renal disease initiating intermittent hemodialysis, administer meropenem 500 mg intravenously after each hemodialysis session. 1

Standard Dosing Regimen

• The recommended dose is 500 mg IV administered immediately after each hemodialysis session to prevent premature drug removal and ensure adequate plasma concentrations. 1
• This post-dialysis dosing follows the standard principle for medications in ESRD patients, preventing the dialysis circuit from clearing the drug before it can exert therapeutic effect. 2
• Hemodialysis removes approximately 50% of meropenem from the circulation, shortening the elimination half-life from 7.0 hours (off dialysis) to 2.9 hours (during dialysis). 1

Pharmacokinetic Rationale

• In anuric patients with end-stage renal disease, meropenem's elimination half-life is prolonged to 7.0–13.7 hours compared to approximately 1 hour in healthy volunteers. 3, 1
• Peak plasma concentrations after 500 mg IV in hemodialysis patients reach approximately 53 mg/L, providing adequate coverage for most pathogens. 3
• Cumulative urinary excretion decreases progressively with declining renal function, making hemodialysis the primary route of drug elimination in ESRD. 1

Alternative Dosing for Continuous Renal Replacement Therapy

• If the patient is receiving continuous venovenous hemofiltration (CVVHF) instead of intermittent HD, increase the dose to 1 g IV every 12 hours because continuous therapies remove 25–50% of meropenem continuously. 3, 4
• For continuous venovenous hemodiafiltration (CVVHDF), the same 1 g every 12 hours regimen maintains plasma concentrations above the MIC₉₀ for Pseudomonas aeruginosa (4 mg/L) during 67% of the dosing interval. 4
• The sieving coefficient of meropenem is 0.93, indicating nearly complete passage across dialysis membranes, which necessitates higher dosing during continuous therapies. 4

Monitoring and Safety Considerations

• Monitor trough levels if available, keeping concentrations below 64 mg/L to minimize neurotoxicity risk, particularly in patients with ESRD where drug accumulation is more likely. 5
• Meropenem has a relatively favorable neurotoxicity profile compared to other beta-lactams (pro-convulsive activity of only 16), making it safer than cefepime or imipenem in ESRF. 5
• When the free minimum concentration normalized to MIC (fCmin/MIC ratio) exceeds 8, significant neurological deterioration occurs in approximately two-thirds of ICU patients, requiring careful monitoring. 5

Critical Pitfalls to Avoid

• Do not administer meropenem before hemodialysis sessions, as approximately 50% of the drug will be removed during dialysis, resulting in subtherapeutic levels. 1
• Do not use the standard 500 mg every 12 hours regimen recommended for patients with creatinine clearance <30 mL/min who are not on dialysis, as this will lead to drug accumulation and potential neurotoxicity in anuric patients. 1
• Avoid underdosing by failing to account for the treatment modality—intermittent HD removes significantly more drug per session than continuous therapies, but the latter provide ongoing clearance requiring higher total daily doses. 3

Dosing Algorithm by Renal Replacement Modality

• Intermittent hemodialysis (3×/week): 500 mg IV after each dialysis session 1
• Sustained low-efficiency dialysis (SLED, 8-hour sessions): 1 g IV every 12 hours during dialysis days, maintaining trough concentrations around 4 mg/L 6
• Continuous venovenous hemofiltration (CVVHF): 1 g IV every 12 hours 4
• Continuous venovenous hemodiafiltration (CVVHDF): 1 g IV every 12 hours 4
• Off dialysis days (anuric patients): 500 mg IV every 24 hours 1

Therapeutic Drug Monitoring

• Peak plasma concentrations should reach 38.9–44.7 mg/L for adequate bacterial killing, while trough concentrations of 7.3–11.9 mg/L maintain efficacy between doses. 7
• For critically ill anuric patients receiving CVVHF, the recommended dose should be increased by 100% compared to standard renal failure dosing to avoid potential underdosing, as hemofiltration contributes significantly to meropenem elimination. 7